卵巢上皮性癌和子宫颈癌患者铂类药物超敏反应及影响因素研究

Study on platinum drug hypersensitivity of patients with epithelial ovarian cancer and cervical cancer and the influencing factors

目的 研究与分析卵巢上皮性癌和子宫颈癌患者铂类药物超敏反应情况及影响因素。方法 选取2018年6月—2019年10月期间诸暨市人民医院采用铂类药物进行化疗的180例卵巢上皮性癌患者和186例子宫颈癌患者为研究对象,将所有患者的铂类药物超敏反应发生情况进行统计,然后比较不同治疗情况、化疗疗程、累积用药量、用药方法及输注时间的卵巢上皮性癌和子宫颈癌患者的发生率,并以多因素Logistic回归分析处理上述因素与卵巢上皮性癌和子宫颈癌患者铂类药物超敏反应的关系。结果 180例卵巢上皮性癌患者发生9例铂类药物超敏反应,发生率为5.00%,186例子宫颈癌患者发生7例铂类药物超敏反应,发生率为3.76%,卵巢上皮性癌和子宫颈癌患者中不同治疗情况、化疗疗程、累积用药量、用药方法及输注时间的发生率存在显著性差异,多因素Logistic回归分析处理显示,上述研究因素均与卵巢上皮性癌和子宫颈癌患者铂类药物超敏反应有密切的关系(均P<0.05)。结论 卵巢上皮性癌和子宫颈癌患者铂类药物超敏反应情况较为严重,且其影响因素较多,因此对卵巢上皮性癌和子宫颈癌患者采用铂类治疗的过程中,应针对此种情况进行干预。

Objective To study and analyze platinum drug hypersensitivity of patients with epithelial ovarian cancer and cervical cancer and the influencing factors. Methods From June 2018 to October 2019, 180 patients with epithelial ovarian cancer and 186 patients with cervical cancer treated with platinum drugs in Zhuji People’s Hospital were selected as study object, platinum drug hypersensitivity situation of all the patients were analyzed, the incidence rates of platinum drug hypersensitivity were compared among epithelial ovarian cancer patients and cervical cancer patients with different treatment situations, chemotherapy treatment courses, cumulative dose, drug application methods, and infusion time, the relationships between those factors and platinum drug hypersensitivity in epithelial ovarian cancer patients and cervical cancer patients were analyzed by multivariate Logistic regression analysis. Results Among 180 patients with epithelial ovarian cancer, 9 patients were found with platinum drug hypersensitivity, the incidence rate was 5.00%;among 186 patients with cervical cancer, 7 patients were found with platinum drug hypersensitivity, the incidence rate was 3.76%. There were statistically significant differences in the incidence rates of platinum drug hypersensitivity among epithelial ovarian cancer patients and cervical cancer patients with different treatment situations, chemotherapy treatment courses, cumulative dose, drug application methods, and infusion time. Multivariate Logistic regression analysis showed that the above-mentioned factors were closely correlated with platinum drug hypersensitivity of epithelial ovarian cancer patients and cervical cancer patients(P<0.05). Conclusion Platinum drug hypersensitivity of patients with epithelial ovarian cancer and cervical cancer is serious, and the influencing factors are various, so interventional measures should be taken in the course of platinum drug treatment in epithelial ovarian cancer patients and cervical cancer patients.